JP2024546018A5 - - Google Patents
Info
- Publication number
- JP2024546018A5 JP2024546018A5 JP2024527417A JP2024527417A JP2024546018A5 JP 2024546018 A5 JP2024546018 A5 JP 2024546018A5 JP 2024527417 A JP2024527417 A JP 2024527417A JP 2024527417 A JP2024527417 A JP 2024527417A JP 2024546018 A5 JP2024546018 A5 JP 2024546018A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cells
- magea1
- peptide
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277924P | 2021-11-10 | 2021-11-10 | |
| US63/277,924 | 2021-11-10 | ||
| US202263317337P | 2022-03-07 | 2022-03-07 | |
| US63/317,337 | 2022-03-07 | ||
| US202263342415P | 2022-05-16 | 2022-05-16 | |
| US63/342,415 | 2022-05-16 | ||
| PCT/US2022/049556 WO2023086480A2 (en) | 2021-11-10 | 2022-11-10 | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546018A JP2024546018A (ja) | 2024-12-17 |
| JP2024546018A5 true JP2024546018A5 (cg-RX-API-DMAC7.html) | 2025-11-18 |
Family
ID=86336428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527417A Pending JP2024546018A (ja) | 2021-11-10 | 2022-11-10 | Magea1免疫原性ペプチド、magea1免疫原性ペプチドを認識する結合性タンパク質、及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230270832A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4430067A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546018A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240112285A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022268347C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3237903A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024007212A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312744A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005746A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340224A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023086480A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116716327B (zh) * | 2023-08-04 | 2023-10-20 | 科士华(南京)生物技术有限公司 | 一种构建tcr载体的方法 |
| KR20260100669A (ko) * | 2023-10-27 | 2026-06-30 | 티스캔 테라퓨틱스, 인크. | Magea1 면역원성 펩티드, magea1 면역원성 펩티드를 인식하는 결합 단백질 및 이의 용도 |
| TWI871128B (zh) * | 2023-12-08 | 2025-01-21 | 陳乃銘 | 可準確提供循環腫瘤細胞(ctc)所需藥物種類之方法 |
| TW202602497A (zh) * | 2024-04-08 | 2026-01-16 | 美商帝斯肯醫療公司 | 結合蛋白用於治療實體腫瘤之用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| WO1995004542A1 (en) * | 1993-08-06 | 1995-02-16 | Cytel Corporation | Cloning and characterization of the complete mage-1 gene |
| US20060073159A1 (en) * | 2004-05-25 | 2006-04-06 | The Trustees Of The University Of Pennsylvania | Human anti-cancer immunotherapy |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2017182528A1 (en) * | 2016-04-19 | 2017-10-26 | Imcyse Sa | Novel immunogenic cd1d binding peptides |
| CA3133945A1 (en) * | 2019-03-25 | 2020-10-01 | University Health Network | T cell receptors and methods of use thereof |
| TWI850360B (zh) * | 2019-04-04 | 2024-08-01 | 德商梅迪基因免疫治療公司 | 黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途 |
| WO2021119545A1 (en) * | 2019-12-11 | 2021-06-17 | Gritstone Bio, Inc. | Durable vaccination |
| EP4090969A1 (en) * | 2020-01-16 | 2022-11-23 | Universität Basel | Mr1 ligands and pharmaceutical compositions for immunomodulation |
| US11464842B1 (en) * | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| EP4519305A4 (en) * | 2022-05-02 | 2026-05-06 | Tscan Therapeutics Inc | Compositions of multiplexed T-lymphocyte receptors, polytherapies and their uses |
-
2022
- 2022-11-10 MX MX2024005746A patent/MX2024005746A/es unknown
- 2022-11-10 IL IL312744A patent/IL312744A/en unknown
- 2022-11-10 KR KR1020247018764A patent/KR20240112285A/ko active Pending
- 2022-11-10 EP EP22893612.6A patent/EP4430067A4/en active Pending
- 2022-11-10 US US17/984,647 patent/US20230270832A1/en active Pending
- 2022-11-10 AU AU2022268347A patent/AU2022268347C1/en active Active
- 2022-11-10 TW TW111143030A patent/TW202340224A/zh unknown
- 2022-11-10 JP JP2024527417A patent/JP2024546018A/ja active Pending
- 2022-11-10 WO PCT/US2022/049556 patent/WO2023086480A2/en not_active Ceased
- 2022-11-10 CA CA3237903A patent/CA3237903A1/en active Pending
-
2024
- 2024-01-26 AU AU2024200495A patent/AU2024200495A1/en active Pending
- 2024-06-07 CO CONC2024/0007212A patent/CO2024007212A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6923714B2 (ja) | Mhcクラスii拘束性mage−a3を認識するt細胞受容体 | |
| CN112979783B (zh) | 获得肿瘤特异性t细胞受体的方法 | |
| EP3241561B1 (en) | Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2 | |
| JP2024515646A5 (cg-RX-API-DMAC7.html) | ||
| KR20200020681A (ko) | Tcr 및 펩티드 | |
| JP2023534808A (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| JP2022554395A5 (cg-RX-API-DMAC7.html) | ||
| JP2025084864A (ja) | T細胞受容体の選択 | |
| US11440956B2 (en) | Anti-thyroglobulin T cell receptors | |
| JP2023550094A5 (cg-RX-API-DMAC7.html) | ||
| CA3115022A1 (en) | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy | |
| Hill et al. | Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a | |
| Nakatsugawa et al. | CD4+ and CD8+ TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells | |
| US20190359677A1 (en) | Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases | |
| KR20250113410A (ko) | 자가면역 장애에 대한 환자 선택 및 치료 모니터링 | |
| Marvel et al. | The CD45RA molecule is expressed in naive murine CTL precursors but absent in memory and effector CTL | |
| JP2025518203A (ja) | Mage-a1特異的tcr及びその用途 | |
| TW202406569A (zh) | 多重t細胞受體組合物、組合療法及其用途 | |
| US12209137B2 (en) | Antigen binding proteins specifically binding CT45 | |
| Shen et al. | Structural and functional characterization of peptide–β2m fused HLA-A2/MART127–35 complexes | |
| EP4223782A1 (en) | Novel t cell receptors and immune therapy using the same for the treatment of cancer | |
| Hess et al. | Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen | |
| WO2026021350A1 (zh) | Tcr键合方式的化学操纵方法及其应用 | |
| JP2007097580A (ja) | T細胞レセプターβ鎖遺伝子 | |
| AU2024374117A1 (en) | Antigen-recognizing construct capable of binding to a frame peptide and a t cell receptor |